INTRODUCTION AND OBJECTIVES: Post-operative delirium is a common complication in the elderly and contributes to increased healthcare costs, mortality, cognitive decline, and hospital length of stay. No definitive pre-operative risk prediction model for patients undergoing major urologic cancer surgeries is currently available.
INTRODUCTION AND OBJECTIVES: To examine if men receiving a prostate cancer diagnosis without evidence of treatment had increased risk of new-onset depression and changes in mental healthrelated quality of life (HRQOL).
METHODS: Using Surveillance, Epidemiology, and End Results -Medicare Health Outcomes Survey (SEER-MHOS) data (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) , we identified localized prostate cancer patients who completed baseline and follow-up HRQOL surveys before/after their cancer diagnosis and were not treated in the interim. Surveys captured major depressive disorder and mental component scores (MCS) of the Veterans RAND 12-item health survey, where higher scores correspond to greater HRQOL. The cohort was divided into 3 subgroups of cases by time between diagnosis and follow-up: <1, 1-3, and >3 years. Cases were matched to controls based on age, marital status, and time between surveys. Bivariate statistics (i.e., Kruskal-Wallis and chi-square tests) were used to evaluate the relationship between incident prostate cancer diagnosis and (a) development of new-onset depression and (b) changes in MCS.
RESULTS: We identified 221 cases matched to 221 controls (n¼126 < 1 yr from diagnosis to follow-up, n¼82 1-3 yr, n¼13 >3 yr). Mean age for subgroups were 75.4 (< 1 yr f/u), 76.6 (1-3 yr f/u), and 78.2 years (>3 yr f/u). Compared to controls, new-onset depression was not more common among prostate cancer patients followed for 1 yr (11.1% vs 8.3% controls, p¼ 0.53) but was more common if followed for 1-3 yr (14.6% vs 4.9% controls, p¼0.04) after diagnosis. Changes in MCS were not significantly greater for cases compared to controls within 1 yr (-0.1 vs -1.4 control, p¼0.27) and from 1-3 yr (-2.5 vs -1.0, p¼0.54) ( Figure) . Among men with <1 yr follow-up, new-onset depression was associated with significant decreases in mental HRQOL (-7.0 vs 0.1 no depression, p¼0.0038). However, changes were not more significant for prostate cancer patients compared to controls (-3.0 vs -12.1 controls, p¼0.15).
CONCLUSIONS: Though more likely to screen positive for new-onset depression, men diagnosed with prostate cancer not receiving treatment did not experience significant changes in overall mental health-related quality of life over time, compared to men without a prostate cancer diagnosis. (FT), an adverse financial condition as a consequence of the treatment of a disease. Evidence suggests that FT is associated with worse mortality, which may be related to impaired health-related quality of life (HRQOL). The purpose of this study is to evaluate the association of FT with HRQOL among patients with bladder cancer.
METHODS: Bladder cancer patients were identified from the University of North Carolina Health Registry/Cancer Survivorship Cohort (HR/CSC), which includes patient-reported data on FT and QOL. FT was defined as agreement with the following statement "you have to pay more for medical care than you can afford." Cancer-specific and general HRQOL was measured using the validated FACT-G, FACT-Bl and PROMIS questionnaires. Bivariate analyses were performed comparing FT and HRQOL scores using Student's t-test.
RESULTS: 144 bladder cancer patients were enrolled in HR/ CSC, of which 138 completed the baseline questionnaire. Median age was 66.9 years. 75% were male, 89% were white, and 66% had less than a college degree. Half of patients had a stage of cT2 or higher. Thirty-three participants overall (24%) endorsed FT. With regard to general HRQOL using the PROMIS questionnaire, patients with FT had worse physical and mental health scores compared to those without FT (p¼0.03 and <0.01, respectively). Patients who endorsed FT also reported lower cancer-specific QOL (72 vs. 81) as well as physical well-being (20.3 vs. 23.0) (p¼0.01). Patients who endorsed FT reported lower functional wellbeing (14.6 vs. 17.8; p¼0.05) . No differences in social well-being, emotional well-being or bladder-cancer specific QOL were noted. CONCLUSIONS: FT is negatively associated with physical and mental health-related quality of life among bladder cancer patients. Our future research will investigate the association between FT and HRQOL as affected by patient-specific characteristics such as demographics, disease stage, and comorbidities. METHODS: Between June 2013 and March 2016, 83 urothelial carcinoma patients who received two courses of neoadjuvant chemotherapy were enrolled in this prospective observational study. Neoadjuvant regimens included gemcitabine+cisplatin (GCis) or gemcitabine+carboplatin (GCb) therapies. As a primary endpoint, we assessed QOL changes in each group before and after chemotherapy using the QLQ questionnaire on days 1, 3, and 15 of each cycle. Secondary endpoints included toxicity, safety, weight loss, renal function decline, and tumor responses.
Source of Funding: none
RESULTS: QOL analyses were performed in 39 patients receiving GCis and in 44 patients receiving GCb. The QOL items appetite loss, role functioning, nausea/vomiting, physical, and fatigue deteriorated >10% from baseline in the GCis group but not in the GCb group. Constipation worsened, whereas scores for pain and emotional items improved in both groups. Objective response rates were 38.5% and 43.2% in the GCis and GCb groups, respectively. CONCLUSIONS: Both GCis and GCb regimens were feasible in terms of QOL. The GCb regimen may be associated with a better QOL status especially in regard to gastrointestinal symptoms.
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